Tenax Therapeutics is trading $1.98 (+6.76%), with the advance appearing sector-driven rather than linked to a fresh company catalyst.

  • No new company-specific announcement was identified for September 3, 2026.
  • Recent company news covered additional Phase 3 LEVEL data, but the primary endpoint failed to reach statistical significance.
  • Broader biotech sentiment is supporting the move, with XBI up 2.75%.